Researchers have identified a promising candidate to combat hepatitis E, a debilitating virus currently lacking approved treatments and responsible for thousands of annual fatalities. The compound, bemnifosbuvir, already undergoing clinical trials for hepatitis C, demonstrates the ability to halt the hepatitis E virus’s replication by interfering with its genetic processes. Laboratory tests conducted on cells and animal models indicate significant efficacy and a favorable safety profile, showing no harm to healthy cells. Should ongoing clinical studies prove successful, bemnifosbuvir could be rapidly repurposed to address hepatitis E, offering a much-needed therapeutic option.
Bemnifosbuvir: Promising New Drug May Finally Stop Hepatitis E
By Rupert Blackwood
Investigative journalist based in Sheffield, focusing on technology's impact on society. Rupert specializes in cybercrime's effect on communities, from online fraud targeting elderly residents to cryptocurrency scams. His reporting examines social media manipulation, digital surveillance, and how criminal networks operate in cyberspace. With expertise in computer systems, he connects technical complexity with real-world consequences for ordinary people